YOLFTbeta
GenixPharmaceucticals Corporation

GenixPharmaceucticals Corporation

GENX · V · Healthcare / Drug Manufacturers - Specialty & Generic

0.02CAD+0.00 (0.00%)

Price History

Full chart

Market Stats

Previous Close0.02
Open0.02
Day Range0.02 – 0.02
52-Week Range0.02 – 0.04
Volume0
Market Cap1.22M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.01
Dividend Yield0.00%
Beta0.48
50-Day Avg0.02
200-Day Avg0.0215

About

Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with a focus on nutraceuticals and pharmaceuticals in Canada. The company offers generic ophthalmic prescription products, ophthalmic nutraceutical formulations, and prescription generic drugs; ophthalmic OTC products; and eye ointments and drops. It also provides Flu-X, an anti-viral, anti-flu, and common colds coronavirus oral and spray herbal product; Rechlor, a dietary supplement to support kidney health; Sucanon, an herbal health supplement to manage blood sugar levels and enhance insulin sensitivity in non-insulin dependent adults; and Synthroid, a levothyroxine sodium drug for the treatment of hypothyroidism. The company was formerly known as Alta Natural Herbs & Supplements Ltd. and changed its name to Genix Pharmaceuticals Corporation in June 2019. Genix Pharmaceuticals Corporation was incorporated in 1993 and is based in Vancouver, Canada.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Sina Salehi Pirooz
  • Employees0
  • Headquarters1055 West Hastings Street, Vancouver, BC, Canada, V6E 2E9, Canada
  • Websitehttps://genixpharm.com

Leadership

  • Mr. Mahmoud S. AzizChairman of the Board & President · b. 1958
  • Mr. Sina Salehi PiroozCEO & Director
  • Mr. Kevin James BottomleyDirector of Corporate Development & Independent Director · b. 1978
  • Ms. Raylen TamayoChief Financial Officer

Financials

Income Statement

Currency: CAD2015-10-312016-10-312017-10-312018-10-312019-10-312020-10-312021-10-312022-10-312023-10-312024-10-312025-10-31
Total Revenue650.86K924.70K1.01M419.96K137.40K00012.35K4.05K0
Growth (%)-+42.07%+9.28%-58.44%-67.28%-100.00%----67.19%-100.00%
Cost of Revenue487.18K513.36K511.31K327.25K183.09K0-09.08K2.75K0
Gross Profit163.68K411.34K499.20K92.72K-45.69K0-03.26K1.30K0
Gross Margin25.15%44.48%49.40%22.08%-33.25%---26.43%32.02%-
Operating Expense690.54K534.74K764.95K117.66K97.65K715.21K-1.03M884.16K242.30K153.28K
Operating Income-526.87K-123.40K-265.75K-24.94K-143.34K-715.21K-1.65M-1.03M-880.89K-241.00K-153.28K
Operating Margin-80.95%-13.35%-26.30%-5.94%-104.32%----7134.48%-5949.22%-
EBITDA---184.79K-23.91K-162.67K-353.21K-1.11M-497.69K-3.80M47.84K-161.79K
EBITDA Margin---18.29%-5.69%-118.39%----30753.83%1180.89%-
Net Income-545.98K-129.05K-243.21K134.07K-164.70K-718.66K-1.65M-1.07M-4.40M-73.20K-335.06K
Net Income Margin-83.89%-13.96%-24.07%31.92%-119.87%----35600.34%-1806.86%-
Interest Expense0008261.78K3.88K3.51K12.13K50.98K119.90K172.14K
Interest Expense % of Total Revenue0.00%0.00%0.00%0.20%1.29%---412.88%2959.81%-

Balance Sheet

Currency: CAD2015-10-312016-10-312017-10-312018-10-312019-10-312020-10-312021-10-312022-10-312023-10-312024-10-312025-10-31
Total Assets617.66K452.47K393.77K231.72K40.27K5.35M4.77M4.25M223.46K45.55K50.98K
Total Liabilities110.78K68.04K272.80K109.15K82.41K489.88K755.19K1.05M1.36M1.23M1.47M
Total Equity506.89K384.43K120.97K122.57K-42.13K4.86M4.01M3.20M-1.14M-1.18M-1.42M
Cash270.01K111.54K101.06K69.90K31.35K696.61K138.81K9.27K11.63K11.48K43.59K
Net Debt-------168.36K499.89K804.18K999.29K

Cash Flow

Currency: CAD2015-10-312016-10-312017-10-312018-10-312019-10-312020-10-312021-10-312022-10-312023-10-312024-10-312025-10-31
Operating Cash Flow-452.55K-165.07K-9.35K34.18K-58.55K-195.03K-428.31K-219.58K-220.67K-187.34K-124.07K
Investing Cash Flow-33.71K-65.34K-65.34K-65.34K-8.00K-8.00K-3.34K-3.34K---
Financing Cash Flow300.00K020.00K20.00K20.00K868.29K-129.48K93.37K223.04K187.19K156.18K
Capital Expenditure33.71K0000003.34K000
Free Cash Flow---9.35K34.18K-58.55K-195.03K-428.31K-222.92K-220.67K-187.34K-124.07K
FCF to OCF--100.00%100.00%100.00%100.00%100.00%101.52%100.00%100.00%100.00%

Earnings

Report DateJan 31, 2008Jul 31, 2009Oct 31, 2009Jan 31, 2010Apr 30, 2010Jul 31, 2010Oct 31, 2010Jan 31, 2011Apr 30, 2011Jul 31, 2011Oct 31, 2011Jan 31, 2012Apr 30, 2012Jul 31, 2012Oct 31, 2012Jan 31, 2013Apr 30, 2013Jul 31, 2013Oct 31, 2013Jan 31, 2014Apr 30, 2014Jul 31, 2014Oct 31, 2014Jan 31, 2015Apr 30, 2015Jul 31, 2015Oct 31, 2015Jan 31, 2016Apr 30, 2016Jul 31, 2016Oct 31, 2016Jan 31, 2017Apr 30, 2017Jul 31, 2017Oct 31, 2017Jan 31, 2018Apr 30, 2018Jul 31, 2018Oct 31, 2018Jan 31, 2019Apr 30, 2019Jul 31, 2019Oct 31, 2019Jan 31, 2020Apr 30, 2020Jul 31, 2020Oct 31, 2020Jan 31, 2021Apr 30, 2021Jul 31, 2021Oct 31, 2021Jan 31, 2022Apr 30, 2022Jul 31, 2022Oct 31, 2022Jan 31, 2023Apr 30, 2023Oct 5, 2026
EPS Estimate----------------------------------------------------------
EPS Actual-0.000.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.000.00-0.000.00-0.00-0.000.00-0.000.00-0.010.000.01-0.00-0.00-0.00-0.00-0.01-0.00-0.00-0.00-0.000.00-0.00-0.00-0.00-0.000.00-0.000.010.00-0.00-0.00-0.00-0.00-0.00-0.00-0.00-0.01-0.01-0.01-0.01-0.01-0.01-0.00-0.00-0.00-0.00-0.00-
Surprise----------------------------------------------------------
Timing---------------------------------------------------------After-hours

Key Statistics & Ratios

Market Cap1.22M
Enterprise Value2.37M
Trailing P/E0.00
Forward P/E0.00
Price / Sales26128.29
Price / Book1.04
EPS-0.01
Book Value-0.025
Revenue (TTM)68
Gross Profit (TTM)-182.99K
EBITDA-124.84K
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-661.13%
Return on Assets-177.39%
Shares Outstanding61.22M
Shares Float33.41M
Beta0.48
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%